František Jurčaga, Miriam Sosková, Zuzana Zelinková, Peter Špalek
Miller Fisher syndrome (MFS) is a variant of Guillain-Barré syndrome (GBS), characterized by a triad consisting of ophthalmoplegia,
areflexia and ataxia. Anti-GQ1b IgG antibodies are present in MFS and are believed to be pathogenic.
Presynaptic neural membranes and perisynaptic Schwann cells are targets for anti-GQ1b antibody attack. We report
a patient with MFS associated with Crohn’s disease (CD). CD together with ulcerative colitis are inflammatory bowel diseases
(IBD). Our paper focuses on pathogenesis, clinical spectrum and treatment of MFS and IDB. Both plasmapheresis
and intravenous immunoglobulin are effective first-line therapies, especially in MFS cases overlapping with GBS.
Treatment for CD usually involves dietary adjustments, anti-inflammatory drugs and biological treatment.